Cargando…

Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis

BACKGROUND: Elevated lipoprotein(a) [Lp(a)] level is an independent genetic risk factor that increases the risk of atherosclerotic cardiovascular disease (ASCVD) by 2–4 fold. We aimed to report the burden of clinically relevant elevated Lp(a) in secondary prevention ASCVD population as the evaluatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orfanos, Panagiotis, Fonseca, Ana Filipa, Hu, Xingdi, Gautam, Raju, Montgomery, Glenn, Studer, Rachel, Kaur, Japinder, Saxena, Nehul, Kaushik, Nitin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659166/ https://www.ncbi.nlm.nih.gov/pubmed/37983217 http://dx.doi.org/10.1371/journal.pone.0294250

Ejemplares similares

Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States
por: Fonseca, Ana F, et al.
Publicado: (2023)

Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study
por: Hu, Xingdi, et al.
Publicado: (2023)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

The HBx Oncoprotein of Hepatitis B Virus Deregulates the Cell Cycle by Promoting the Intracellular Accumulation and Re-Compartmentalization of the Cellular Deubiquitinase USP37
por: Saxena, Nehul, et al.
Publicado: (2014)

Associations of Lipoprotein(a) With Coronary Atherosclerotic Burden and All-Cause Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
por: Xue, Yuzhou, et al.
Publicado: (2021)

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
por: Lampsas, Stamatios, et al.
Publicado: (2023)

Association of Lipoprotein(a) With Atherosclerotic Plaque Progression
por: Kaiser, Yannick, et al.
Publicado: (2022)

Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease
por: Niccoli, Giampaolo, et al.
Publicado: (2016)

Serum lipoprotein (a) and atherosclerotic changes in hemodialysis patients
por: Rafieian-Kopaei, Mahmoud, et al.
Publicado: (2013)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease
por: Tmoyan, Narek A., et al.
Publicado: (2021)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

High-Density Lipoprotein Nanoparticle Imaging in Atherosclerotic Vascular Disease
por: Leeper, Nicholas J., et al.
Publicado: (2017)

Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
por: Reiner, Željko
Publicado: (2018)

Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases
por: Ivanova, Ekaterina A., et al.
Publicado: (2017)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
por: Desai, Nihar R., et al.
Publicado: (2022)

Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden
por: Eržen, Barbara, et al.
Publicado: (2014)

Association of trimethylamine N-oxide with coronary atherosclerotic burden in patients with non-ST-segment elevation myocardial infarction
por: Bin Waleed, Khalid, et al.
Publicado: (2020)

Caregivers of Patients with Heart Failure: Burden and the Determinants of Health-Related Quality of Life
por: Lahoz, Raquel, et al.
Publicado: (2021)

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification—A Deep Connection
por: Torzewski, Michael
Publicado: (2021)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
por: Makris, Anastasios, et al.
Publicado: (2023)

Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels
por: Ezhov, Marat, et al.
Publicado: (2019)

Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
por: Sukkari, Mohamad Hekmat, et al.
Publicado: (2023)

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease
por: Ito, Fumiaki, et al.
Publicado: (2020)

Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits
por: LI, CHEN, et al.
Publicado: (2015)

Weight Gain After Smoking Cessation and Atherosclerotic Low-Density Lipoprotein Marker
por: Iida, Mami
Publicado: (2016)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease
por: Gao, Shen, et al.
Publicado: (2017)

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
por: Tada, Hayato, et al.
Publicado: (2019)

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
por: Wong, Nathan D.
Publicado: (2022)

Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
por: Clarke, Shoa L.
Publicado: (2023)

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
por: Fuior, Elena Valeria, et al.
Publicado: (2023)

Lipoprotein(a) Is Associated with Thrombus Burden in Culprit Arteries of Younger Patients with ST-Segment Elevation Myocardial Infarction
por: Sankhesara, Dipen M., et al.
Publicado: (2023)

Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study
por: Fonseca, Ana Filipa, et al.
Publicado: (2021)

Elevated homocysteine as an independent risk for intracranial atherosclerotic stenosis
por: Liu, Ying, et al.
Publicado: (2019)

Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)
por: Chakraborty, Anindita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0lajfi3f2ke1o1vi7ud8p3c660